American Society of Hirudotherapy

The Use of Bivalirudin in ST-Segment Elevation Myocardial Infarction: Advantages and Limitations

Review published in Interv Cardiol Clin (2012)

Last Updated: June 18, 2026Reviewed by: ASH Editorial Board
Research article — evidence reviewArticle reference
Evidence: Narrative reviewDrug DevelopmentClinical TrialsSergie Z et al. · Interv Cardiol Clin, 2012

Abstract

The incidence of ST-segment elevation myocardial infarction (STEMI) is a common, albeit declining, manifestation of coronary heart disease. Significant improvements in cardiovascular outcomes and mortality in STEMI patients have occurred in recent years, reflecting evolution in the understanding of the pathophysiological mechanisms and therapeutic targets of this disease. Nonetheless, the risks of recurrent ischemia and bleeding complications in this population remain substantial. This review focuses on the adjunctive anticoagulant agents used in the management of STEMI. Major insights from the HORIZONS-AMI trial regarding the impact of bivalirudin on both hemorrhagic and ischemic outcomes in STEMI patients are discussed.

Abstract sourced from PubMed (NCBI) for the cited record. See the original publication for the authoritative version.

Publication typeJournal ArticleReview

Summary

The incidence of ST-segment elevation myocardial infarction (STEMI) is a common, albeit declining, manifestation of coronary heart disease.

Why This Matters for Hirudotherapy

This review examines adjunctive anticoagulant agents used in the management of ST-segment elevation myocardial infarction (STEMI), including insights from the HORIZONS-AMI trial regarding the impact of bivalirudin on both hemorrhagic and ischemic outcomes. As a review of anticoagulation strategies in interventional cardiology, it addresses clinical pharmacotherapy without involving leeches, leech therapy, or leech-derived molecules. The abstract provides no information linking bivalirudin to hirudin, the leech secretome, or any aspect of hirudotherapy. Consequently, this article has no demonstrable relevance to ASH's domain beyond the general topic of anticoagulant pharmacotherapy.

Citation

The Use of Bivalirudin in ST-Segment Elevation Myocardial Infarction: Advantages and Limitations.

Sergie Z et al. · Interv Cardiol Clin, 2012

DOI

Added to ASH library: May 27, 2026 · Site last updated: June 18, 2026

This website provides educational information and does not constitute medical advice, diagnosis, or treatment recommendations. Medicinal leech therapy carries clinically meaningful risks and should be performed only by qualified clinicians under institutionally approved protocols. FDA 510(k) clearance for medicinal leeches is limited to specific indications; investigational and off-label discussions are labeled accordingly. For patient-specific guidance, consult a qualified healthcare provider.